Cite
Gazitt Y, Cantor A, He Y, et al. Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment - tumor-cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery. Int J Oncol. 1993;3(4):755-61doi: 10.3892/ijo.3.4.755.
Gazitt, Y., Cantor, A., He, Y., Koza, S., Cohen, R., & Grahampole, J. (1993). Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment - tumor-cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery. International journal of oncology, 3(4), 755-61. https://doi.org/10.3892/ijo.3.4.755
Gazitt, Y, et al. "Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment - tumor-cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery." International journal of oncology vol. 3,4 (1993): 755-61. doi: https://doi.org/10.3892/ijo.3.4.755
Gazitt Y, Cantor A, He Y, Koza S, Cohen R, Grahampole J. Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment - tumor-cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery. Int J Oncol. 1993 Oct;3(4):755-61. doi: 10.3892/ijo.3.4.755. PMID: 21573429.
Copy
Download .nbib